Evolving CML Treatment, Adverse Event Management, and Optimizing Patient Care
Javier Pinilla, MD, PhD, and Lauren Verity Moore, DNP, MSN, AGACNP-BC, discuss how the evolving landscape of chronic myeloid leukemia (CML) treatment has improved patient outcomes through new drug formulations such as nilotinib without fasting requirements, emphasizing the critical roles of medication adherence, comprehensive adverse effect management, multidisciplinary care teams, and shared decision-making to ensure both effective disease control and optimal quality of life for patients living with this now-manageable chronic condition.
EP. 1: How Has the CML Treatment Landscape Evolved Over the Past 5 Years?
April 10th 2025Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect management, tailored treatment approaches through molecular monitoring, and increased emphasis on shared decision-making with patients.
EP. 2: Understanding the Significance of Nilotinib's New Formulation
April 10th 2025Panelists discuss how the new FDA-approved formulation of nilotinib offers significant advantages over the original version by eliminating fasting requirements, potentially improving patient adherence while maintaining efficacy and reducing the risk of toxicity-related complications such as glucose metabolism issues, elevated cholesterol, and pancreatitis.
